Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) EBITDA (2019 - 2026)

Vaxcyte (PCVX) has 8 years of EBITDA data on record, last reported at -$329.0 million in Q1 2026.

  • On a quarterly basis, EBITDA fell 139.88% to -$329.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$953.0 million, a 85.84% decrease, with the full-year FY2025 number at -$761.2 million, down 62.65% from a year prior.
  • EBITDA reached -$329.0 million in Q1 2026 per PCVX's latest filing, down from -$245.8 million in the prior quarter.
  • Over the last five years, EBITDA for PCVX hit a ceiling of -$39.6 million in Q1 2022 and a floor of -$329.0 million in Q1 2026.
  • A 5-year average of -$129.0 million and a median of -$104.8 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 190.07% in 2022, then rose 20.88% in 2024.
  • Tracing PCVX's EBITDA over 5 years: stood at -$86.6 million in 2022, then crashed by 105.99% to -$178.3 million in 2023, then grew by 20.88% to -$141.1 million in 2024, then tumbled by 74.2% to -$245.8 million in 2025, then crashed by 33.88% to -$329.0 million in 2026.
  • Business Quant data shows EBITDA for PCVX at -$329.0 million in Q1 2026, -$245.8 million in Q4 2025, and -$210.1 million in Q3 2025.